Narcolepsy Treatments
An expert discusses treatments for narcolepsy, comparing options for managing excessive daytime sleepiness (EDS) and cataplexy, and examines the advantages, limitations, and clinical scenarios for medications targeting EDS versus compared with those for both EDS and cataplexy.
Video content above is prompted by the following:
- What are the currently available treatments for narcolepsy, and how do they address different aspects of the condition, such as EDS and cataplexy?
- What are the comparative advantages and limitations of stimulant medications, wake-promoting agents, and other therapeutic options for managing EDS?
- How does do efficacy and adverse event profiles of medications specifically targeting EDS (eg, modafinil, armodafinil, solriamfetol, and pitolisant) compare to with those approved for both EDS and cataplexy (eg, sodium oxybate, and low-sodium oxybate)? In what scenarios would one category of medication be preferred over the other in clinical practice?
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Optimizing narcolepsy care: Diagnosis, treatment and patient access | Written recap
August 6th 2025In a recent Managed Healthcare Executive K-Cast video series, R. Robert Auger, M.D., a psychiatrist and sleep specialist at the Mayo Clinic in Rochester, Minnesota, spoke about the diagnosis and treatment of narcolepsy and idiopathic hypersomnia. This is a written recap of that series.
Read More
Value-Based Decision-Making in Metastatic Breast Cancer
August 6th 2025In this Managed Healthcare Executive® KCast, Ian Krop, M.D., Ph.D., oncologist and associate professor of medicine at Dana-Farber Cancer Institute in Boston, and Debra Patt, M.D., Ph.D., MBA, executive vice president at Texas Oncology in Austin, provide key insights into the value-based care model for patients with HER2-positive metastatic breast cancer (mBC). This article summarizes the highlights of the discussion.
Read More
